UmbriaExplore our travel guides. Share your stories, tips and questions on Reddit.
Fast movers • Alerts • Momentum
10% OFF with SAVE10
Charts • Watchlists • Multi-broker tools
Built for active traders
Biotech catalyst, news and analysis PDUFA tracker
Biotech catalyst, news and analysis PDUFA tracker
September 25, 2026: Fate announces a $15 million CIRM CLIN2 grant for the ongoing RECLAIM-LN trial of FT819 in refractory lupus nephritis. The award supports development; it does not establish that all funds have been received or provide new efficacy results.
Get every Merlintrader report in real time on Telegram: join @merlintraderpub_com.
The ACR posters cover FT839 in rheumatoid arthritis (November 8) and FT819 outpatient dosing, SLE fatigue biomarkers and a patient-preference study (November 9); the release gives no new efficacy figures. Fate expects the next FT836 clinical update in the first half of 2027. The CCR West presentation of September 18 has taken place. The September 25 CIRM grant is a funding development; it does not announce a new efficacy-readout date.
The catalyst calendar distinguishes confirmed dates from company guidance and registry estimates.
Two potentially registrational and Phase 1/2 autoimmune programs are now on the registry with recruiting status: RECLAIM-LN with twelve U.S. sites recruiting at the September 14 registry update and a first patient dosed as an outpatient and discharged the same day from on-demand inventory, and FT839 COMPLETE, posted on September 2, 2026 across five autoimmune diseases. The FT819 Phase 1 dataset behind them showed no dose-limiting toxicities, no Grade 3 or higher cytokine release syndrome, no ICANS and no graft-versus-host disease in the 16 SLE patients treated under the less-intensive Regimen A at the May 14 cutoff, out of 21 treated in all, with the top 50 autoreactive B-cell clones reduced by 74% to 96% in the five patients sequenced. FDA has granted RMAT and admitted FT819 to the CMC Development and Readiness Pilot, and the pivotal drug-product batch is manufactured and released. Cash, cash equivalents and investments were $153.8 million at June 30, 2026 with company guidance into 2028, and no ATM sales through quarter-end. The off-the-shelf iPSC model is the differentiator against autologous CAR-T in autoimmunity, where the argument is access and cost as much as efficacy.
Nothing in the Phase 2 has read out. RECLAIM-LN needs about 53 refractory patients, the company’s own enrolment window runs to the first half of 2028 and the registry places primary completion in July 2029; the primary endpoint, complete renal response at week 26, has not been met by any FT819 patient in a controlled setting because there has been no controlled setting. The Phase 1 evidence is open-label, small and spread across conditioning regimens. FT839 has no human data, its registry design now includes conditioning arms the August description did not mention, and one recruiting site is not a running trial. The quarterly net loss was $30.2 million against $2.1 million of collaboration revenue, and the fully diluted count includes pre-funded warrants, convertible preferred stock, options, restricted stock units and an expanded equity-plan reserve registered on Form S-8 on August 13. Finviz reports short interest at 7.46% of the float on September 6, 2026. The ACR posters of November 8–9 are dated; the first efficacy read is not.
Cash, equivalents and investments were $153.8 million at June 30, 2026; first-half operating cash use was $54.3 million. Management guided funding into 2028 under its plan, with no ATM sales through quarter-end. This is historical liquidity and conditional guidance, not an October balance. Q2 Form 10-Q
The $15 million CIRM award supports RECLAIM-LN but does not establish full receipt of cash. Enrollment, renal outcomes and manufacturing execution remain the operating tests.
September 25 update: the CIRM award adds program-specific support. The central questions remain enrollment, renal outcomes and manufacturing execution; funding an experiment does not establish its result.
Fate Therapeutics is a high-risk platform story in cell therapy that sits at the intersection of two major biotech questions: can engineered cellular therapy move beyond individualized autologous manufacturing, and can CAR-T biology be translated from oncology into autoimmune disease in a way that is clinically durable, operationally practical and commercially scalable?
The company’s current thesis is much narrower than the broad, collaboration-heavy oncology narrative that drove the stock during the early cell-therapy boom. Fate has rebuilt around induced pluripotent stem cell-derived, off-the-shelf cellular immunotherapies that are designed to address manufacturing variability, patient-specific production delays, complex logistics and constrained treatment-center access. The strategic premise still depends on clinical evidence, manufacturing discipline and regulatory execution.
At the center of the story is FT819, an off-the-shelf, CD19-targeted, iPSC-derived CAR-T candidate being evaluated across systemic lupus erythematosus, lupus nephritis, systemic sclerosis and other B-cell-mediated autoimmune diseases. The scientific thesis is that deep B-cell depletion and immune remodeling may produce a meaningful immune reset. The practical thesis is that an inventory-based product could be available on demand and potentially administered with less-intensive conditioning than conventional autologous CAR-T.
Fate announced October 1 awards of 62,900 options at $2.30 to one employee and 72,700 restricted stock units to two employees, including the option recipient. Both vest over four years; these awards are not all immediately issued common shares.
A separate October 1 announcement lists Jefferies London on November 16–19 and Piper Sandler New York on December 1–3, without specific presentation times. ACR November 8–9 remains the next scheduled clinical presentation program.
This is development funding, not a new clinical readout or trial launch. Fate does not confirm receipt of the full award or quantify a revised cash runway.
Fate presented previously disclosed Phase 1 FT819 data in SLE and preclinical FT839 data on September 18, 2026 at 3:40 p.m. Pacific. The FT819 analysis covers 16 Regimen A patients receiving less-intensive, fludarabine-free conditioning; 13 had at least one month of follow-up at the May 14, 2026 cutoff. This is an encore presentation, not new RECLAIM-LN efficacy data.
The September conferences, Cantor on September 9, Wells Fargo on September 8–10 and H.C. Wainwright through September 16, and the CCR West presentation of September 18 have passed. The next confirmed presentations are the ACR posters on November 8–9 at 10:30 a.m.–12:30 p.m. ET. These appearances must be distinguished from trial enrollment and regulatory milestones.
The registry record for FT839 in autoimmune diseases appeared on September 2, 2026 with overall status Recruiting and one site listed, in Fullerton, California. It describes an open-label, multicenter Phase 1/2 dose-escalation and expansion trial with 446 participants estimated, adults aged 18 to 70, an estimated start in October 2026 and primary completion in October 2028, in ANCA-associated vasculitis, idiopathic inflammatory myositis, rheumatoid arthritis, systemic lupus erythematosus and systemic sclerosis. There are eight regimens: four without conditioning, with or without rituximab and with or without stable background therapy, and four with conditioning. The company’s August 13 description spoke of a no-conditioning protocol at 900 million cells with background standard therapy; the registry design is broader than that and includes conditioning arms, which is the sponsor’s own filing and is reported here as it stands. The RECLAIM-LN record subsequently listed twelve recruiting U.S. sites in its September 14 update; the September 2 FT836 record listed eight regimens and 119 participants.
The full deep dive has the answer’s building blocks: cash, dilution, catalysts and risks, every figure sourced.
Free. No signup. You decide, we don’t recommend.
Scenario reset after Q2: the first-dose milestone raises execution confidence modestly, while the $153.8 million balance and H1 2028 enrollment target make financing timing more central. Scenario analysis should now assign less weight to launch uncertainty and more weight to enrollment cadence, renal efficacy, CMC comparability and capital consumed before meaningful data.
FT819 continues to show credible clinical responses, durable immune remodeling and a favorable safety profile. RECLAIM-LN, with its first patient dosed, delivers efficient enrollment across its twelve recruiting sites, while FDA interactions support a practical path. FT839 enters Phase 1/2 cleanly and begins to validate dual CD19/CD38 targeting. Reduced-conditioning or no-conditioning approaches strengthen the commercial-access story.
FT819 remains promising but still early. RECLAIM-LN enrollment begins gradually and requires time before six-month renal data become available, while FT839 starts clinical development without immediately producing decision-grade human evidence. Cash runway supports development, but dilution remains part of the equation. Oncology programs add optionality without becoming near-term valuation drivers.
FT819 data fail to scale, durability weakens, safety or conditioning requirements become less favorable, or the regulatory path proves slower than hoped. FT839 enrollment or manufacturing is delayed, or its complex design creates tolerability and persistence problems. Financing pressure rises before definitive data arrive.
This page reads $FATE as a platform company that has narrowed to one thesis it can test: FT819 in autoimmune disease, with RECLAIM-LN first-patient dosing announced in August 2026, a $15 million CIRM grant behind it, $153.8 million of cash and investments at June 30, 2026 and company guidance into 2028. These observations would change that reading.
None of these is a prediction. They are the observations that would make the rest of this page wrong, listed so that a reader can check them rather than take the reading on trust.
The real promise of Fate’s approach is not only that the cells are engineered. It is that the engineering can be locked into a clonal master iPSC line and then used repeatedly as the source for future drug product. In an ideal version of the model, one carefully characterized starting line can support batch manufacturing, quality control, release testing and inventory planning in a way that looks more like a standardized biologic than a bespoke cell therapy procedure.
That matters for patients and for the healthcare system. A patient-specific CAR-T product begins with a patient whose immune system may already be damaged by disease, prior therapies or age. The starting material can be inconsistent. Manufacturing can fail. Time from cell collection to infusion can be clinically meaningful. An off-the-shelf product tries to change that equation by separating manufacturing from the individual patient’s immediate clinical condition.
The difficulty is that off-the-shelf cell therapy creates its own problems. Cells derived from a donor-like or engineered source can be recognized and rejected by the patient’s immune system. Persistence may be shorter than with autologous products. Re-dosing strategies must be carefully tested. Manufacturing consistency must be proven across lots. Regulators need to understand the product’s identity, potency and comparability. None of these are trivial requirements.
Lupus nephritis is not just another autoimmune indication. It is a severe organ-threatening manifestation of SLE, and it gives Fate a development setting where the unmet need is real, the clinical consequences are serious and renal endpoints can potentially provide a clearer efficacy framework than broader symptom-based autoimmune measures. That makes it a logical place to test whether FT819 can do more than generate interesting immune biomarker movement.
The challenge is that lupus nephritis is also heterogeneous and difficult. Background therapy, steroid use, renal biopsy history, baseline proteinuria, kidney function, prior biologics and immunosuppressant exposure can all affect interpretation. A clean response in one patient is encouraging, but the market will eventually need to understand how the therapy performs across different disease histories and baseline risk profiles.
The RECLAIM-LN path, now open, is therefore a major credibility step. A Phase 2 potentially registrational study will put pressure on the program to define a dose, conditioning regimen, primary endpoint and response window that can stand up to regulatory and investor scrutiny. The fact that Fate developed the study through FDA interactions under RMAT is encouraging, but it does not eliminate the need for robust clinical execution.
One of the most important strategic questions around FT819 is how much conditioning chemotherapy is truly needed. In autoimmune disease, the ideal commercial therapy would minimize pre-treatment burden while still achieving enough cell expansion, B-cell depletion and immune remodeling to produce durable clinical benefit. The less intensive the preparation, the broader the potential patient pool may become.
This is why Fate’s no-conditioning and reduced-conditioning data are more than technical details. They go directly to the commercial identity of the product. If FT819 can work with less intensive preparation, the therapy could be easier to place in autoimmune treatment algorithms. If robust activity requires heavier conditioning, the program may still be valuable, but adoption could be narrower and more specialized.
The core question: can FT819 move from promising early autoimmune CAR-T signal to a scalable, practical, regulatory-grade therapy? That is the difference between an interesting platform story and a potentially major biotech asset.
Fate presented previously disclosed Phase 1 FT819 data in SLE and preclinical FT839 data on September 18, 2026 at 3:40 p.m. Pacific. The FT819 analysis covers 16 Regimen A patients receiving less-intensive, fludarabine-free conditioning; 13 had at least one month of follow-up at the May 14, 2026 cutoff. This is an encore presentation, not new RECLAIM-LN efficacy data.
The company reports no dose-limiting toxicities, Grade 3 or higher CRS, ICANS, GvHD or IEC-HS in Regimen A, with infections and cytopenias described as low and manageable. In patients with active lupus nephritis at baseline, it reports Month 6 UPCr decreases of 1.15 g/g in Regimen A and 1.8 g/g in the bendamustine subgroup. The release does not specify the size of these Month 6 renal subgroups. These preliminary Phase 1 observations do not establish Phase 2 efficacy; FT839 findings at this event are preclinical.
September 25 context: the grant supports the existing open-label, single-arm RECLAIM-LN study, targeting approximately 53 participants and complete renal response at week 26. No new response data accompany the award. Those design limits still govern how future results should be read. Company release.
Current verified status: first patient dosed, multiple U.S. sites activated, additional patients in screening and UK MHRA authorization received. The protocol remains open-label and single-arm, with one 900-million-cell FT819 dose after bendamustine and complete renal response at week 26 as the primary endpoint. Fate now aims to complete enrollment in H1 2028.
RECLAIM-LN is the central development program for the FATE story. FT819-201 is a Phase 2, open-label, single-arm, potentially registrational study in patients with refractory moderate-to-severe systemic lupus erythematosus with Class III or IV lupus nephritis, with or without concomitant Class V involvement. Fate has described a target enrollment of approximately 53 participants, one 900 million-cell dose of FT819 after bendamustine conditioning and complete renal response at six months as the primary endpoint.
The key July update is that recruitment has moved from corporate guidance into visible patient-facing execution. Fate’s clinical-trials page now includes a dedicated RECLAIM-LN section, while the company’s July 7 recruitment brochure says the study is enrolling people aged 12 to 70 whose lupus nephritis has not responded adequately to current treatment. The brochure describes screening, preparatory medicines, a single intravenous infusion, seven days of monitoring, a three-day hospital stay, follow-up visits for up to two years and long-term safety follow-up extending to 15 years after treatment. This July brochure is an earlier description; the later Q2 company update specifically reported the first patient treated in an outpatient setting. The older hospital-stay description should not be treated as a universal current requirement.
That operational detail matters because trial activation is often the point at which an ambitious development plan encounters the real-world constraints of site contracting, investigator readiness, patient eligibility, screening failures, scheduling and treatment logistics. Fate’s on-demand inventory model should theoretically reduce one major source of delay: there is no need to manufacture a bespoke product from each patient’s own cells. The remaining question is whether that advantage translates into faster screening-to-dose timing and reliable enrollment across sites.
The distinction is important for investors. A trial may be described as enrolling while sites are opening, patients are being identified or screening is underway. The first-dose milestone requires a higher level of confirmation because it establishes that eligibility, conditioning, product delivery and infusion logistics have all been completed for at least one participant. Fate confirmed that milestone on August 13: the current status is first patient dosed, multiple sites active and additional patients screening.
The selected bendamustine-only conditioning regimen is less intensive than the multi-day cyclophosphamide-plus-fludarabine regimens commonly used in conventional CAR-T programs. Fate has said the design reflects feedback from its Phase 1 experience and is intended to improve patient and physician acceptance. The study also matters because lupus nephritis provides a more organ-specific framework than broad symptom measures alone: renal response, proteinuria, kidney function, steroid reduction and durability can create a more decision-useful dataset.
Fate now aims to complete enrollment in the first half of 2028, based on Phase 1 enrollment cadence, site engagement, on-demand product availability and outpatient-treatment potential. That goal should now be judged against hard operating evidence: number of activated sites (twelve recruiting on the registry at September 14, 2026), time from screening to infusion, screen-failure rates and the pace at which participants move through treatment.
What changes the thesis next: the recruitment launch is constructive, but the true de-risking sequence is first dose, repeatable enrollment, manageable conditioning and safety, then credible complete renal responses at the six-month endpoint. Every step reduces a different category of risk.
Q2 CMC update: the pivotal FT819 batch has been manufactured and released, inventory is positioned in depots, and Fate says potency, release assays and key CMC elements have been discussed and aligned with the FDA under RMAT interactions. CDRP work continues. This reduces launch-process uncertainty but does not pre-approve the eventual biologics license package.
FT819 has FDA Regenerative Medicine Advanced Therapy designation for moderate-to-severe SLE and was selected for the FDA’s Chemistry, Manufacturing and Controls Development and Readiness Pilot program. For a normal small-molecule story, investors often focus mainly on clinical endpoints and safety. In cell therapy, that is not enough. The product is the process.
Regulators need to know that the cells used in subsequent treatment are meaningfully comparable to the cells used in earlier studies, that potency assays are relevant, that lot-to-lot variability is controlled and that the company can scale without changing the product in ways that undermine the clinical package. For Fate, CMC is even more central because the iPSC platform is part of the claimed advantage. The company is effectively arguing that its manufacturing architecture can produce more standardized, more accessible cell therapy products. If that claim is true, CMC becomes a strength. If the manufacturing package proves difficult, delayed or hard to validate, the same platform complexity can become a bottleneck.
CDRP selection does not mean the FDA has blessed FT819 or guaranteed approval. It means Fate can have enhanced and earlier FDA interaction on CMC readiness, manufacturing strategy and development alignment. For a company trying to build an off-the-shelf cell therapy business, that kind of interaction can be strategically valuable, especially if the clinical program is being positioned for accelerated timelines.
Current protocol: COMPLETE (FT839-101) will start at 900 million cells with background standard therapy and no conditioning required. Fate is accelerating site activation and expects an enrollment update later in 2026. The registry record posted on September 2, 2026 nevertheless includes four regimens with conditioning alongside four without: the no-conditioning description is the company’s stated starting protocol, not the whole design.
FT839 is Fate’s first multi-antigen dual-CAR T-cell product candidate. It is designed to express one CAR targeting CD19 and another targeting CD38, with the goal of addressing complex multicellular autoimmune disease by targeting B-cell lineage populations, plasma cells and activated immune cells. It also incorporates Fate’s Sword & Shield technology, which is intended to help the product resist host allogeneic immune responses and reduce dependence on conditioning chemotherapy.
FDA clearance of the FT839 IND on July 9, 2026 moved the program into clinical development. Fate plans to begin enrollment in a Phase 1/2 multi-indication basket trial during the second half of 2026; the record, NCT07800871, was posted on September 2, 2026 as Recruiting at one site with an estimated October 2026 start. The protocol is designed to evaluate FT839 at 900 million cells with standard-of-care therapy and no required conditioning, across rheumatoid arthritis, ANCA-associated vasculitis, idiopathic inflammatory myositis, SLE with or without nephritis, and systemic sclerosis.
The program’s engineering is unusually complex. Fate describes FT839 as a 13-point edited CAR-T product incorporating dual CD19 and CD38 CARs; hnCD16 to support combinations with therapeutic monoclonal antibodies; a CD3 fusion receptor to support combinations with T-cell engagers; Sword & Shield technology; CXCR2 and a TGF-beta signal redirection receptor intended to improve trafficking and function in difficult tissue environments; and CD38 and TRAC knockouts intended to support metabolic fitness and reduce graft-versus-host-disease risk.
Preclinical data presented at ASGCT and EULAR 2026 showed selective elimination of CD19-positive B cells, plasmablasts, CD38-positive plasma cells and activated CD38-positive T cells while preserving non-activated CD38-negative T cells. Those data supported the IND, but the program must now demonstrate whether the same biological logic can translate into acceptable safety, persistence and useful clinical activity in patients.
Q2 development decision: based on preliminary activity in two KRAS-wild-type metastatic colorectal-cancer patients, Fate will focus the next cohort on that population using multidose FT836 with standard chemotherapy. The next clinical update is expected in H1 2027. A separate FDA-cleared investigator-initiated multiple-myeloma study will combine FT836 with daratumumab.
FT836 is Fate’s next-generation MICA/B-targeted, multipoint-edited, off-the-shelf CAR-T product candidate for advanced solid tumors. Solid-tumor CAR-T is one of the hardest areas in oncology drug development because of antigen heterogeneity, trafficking, tumor microenvironment suppression, persistence challenges and safety concerns. That is why any early signal must be treated carefully, but also why a real human signal can draw attention.
At ASCO 2026, Fate presented preliminary Phase 1 data. As of the April 20, 2026 cutoff, nine patients had been enrolled across two regimens: FT836 plus cetuximab and FT836 plus trastuzumab. Both regimens were administered without conditioning chemotherapy. All nine patients were evaluable for safety, and five were available for initial efficacy assessment. Fate reported no dose-limiting toxicities, no cytokine release syndrome, no ICANS and no graft-versus-host disease across treated patients and dose levels.
The most notable signal came from two heavily pre-treated KRAS wild-type metastatic colorectal cancer patients in the cetuximab combination arm, each with seven prior lines of therapy. Fate reported meaningful target-lesion reductions and tumor biomarker decreases, including CEA decline, and stated that it plans to focus on this colorectal cancer patient population based on the early findings.
This is still an early dataset and should not be overread. The patient numbers are tiny, there is no randomized comparison and the activity needs to be replicated in a larger cohort. But the ASCO update gives Fate a human solid-tumor signal showing FT836 trafficking and preliminary anti-tumor activity without conditioning chemotherapy. That keeps oncology optionality alive while autoimmune disease remains the main story.
September 25 funding update: CIRM’s $15 million award is not a confirmed addition of the same amount to current cash. The release does not disclose full disbursement, payment tranches or a quantified revision to runway guidance. The June 30 balances below remain dated financial statements, not a September cash estimate. Fate grant announcement.
| Metric | Q2 2026 | Q2 2025 | Investor reading |
|---|---|---|---|
| Collaboration revenue | $2.082M | $1.907M | Still small and timing-driven; it is not commercial product revenue. |
| R&D expense | $24.387M | $27.430M | Down $3.043M year over year despite clinical-trial expense increasing by $1.7M. |
| G&A expense | $8.829M | $11.445M | Down $2.616M, helped by lower stock compensation, consulting and legal costs. |
| Total operating expense | $33.216M | $38.875M | Down $5.659M, or about 14.6%, while the company advanced three clinical programs. |
| Operating loss | $(31.134)M | $(36.968)M | The core loss narrowed by $5.834M. |
| Net loss / EPS | $(30.159)M / $(0.25) | $(34.070)M / $(0.29) | GAAP net loss remained close to operating loss; basic and diluted EPS are identical in a loss period. |
| Stock-based compensation | $3.518M | Included in expenses | Non-cash, but economically relevant because awards expand the fully diluted claim on equity. |
Earnings quality: Q2 other income was $1.0 million net, principally $1.6 million of interest income partly offset by a $0.6 million fair-value charge. There was no large one-off accounting gain masking the operating loss. The quarter is therefore best read as a controlled-cost development period, not an inflection in recurring revenue or profitability.
For the first six months of 2026, operating expenses were $67.5 million, down $14.3 million year over year; net loss was $61.4 million; and cash used in operating activities was $54.3 million, versus $58.4 million in the prior-year period. The roughly $21.0 million sequential decline in cash and investments is useful, but should not be annualized mechanically because working capital, investment maturities and payment timing vary.
At June 30, Fate held $32.429 million of cash and cash equivalents and $121.341 million of short-term investments, totaling $153.770 million. Restricted cash of $10.050 million is separate and should not be counted as freely deployable runway. Current assets were $157.953 million against current liabilities of $32.592 million. Operating-lease liabilities totaled $75.675 million on the balance sheet, with $113.838 million of future undiscounted lease payments.
Management’s release says existing capital supports operations into 2028. The statutory 10-Q liquidity statement is narrower: available resources are expected to fund operating expenses and capital requirements for at least twelve months from filing. These statements are compatible but not interchangeable; the longer horizon is company guidance and remains sensitive to enrollment pace, program choices, manufacturing spend and future financing.
Fate reported 116.694 million common shares, 3.894 million pre-funded warrants and 2.755 million Class A preferred shares. Each preferred share converts into five common shares, equal to 13.775 million common-share equivalents. Common shares plus pre-funded warrants plus preferred as converted therefore represent approximately 134.363 million economic share equivalents before employee equity awards.
Outstanding options covered 16.351 million shares at a weighted-average exercise price of $6.42, and unvested RSUs covered 9.000 million shares. Including those instruments produces approximately 159.714 million potential share equivalents; this is a dilution inventory, not a prediction that every instrument will vest, convert or be exercised. Most options are economically less relevant while the market price stays well below the $6.42 weighted-average strike, as it did at the $2.48 close of September 4, 2026.
The shelf-registration framework retained approximately $220 million of capacity after the March 2024 offering, including a $100 million ATM facility. Fate reported no ATM sales through June 30, 2026. The company also carries $11.885 million of current and long-term CIRM liabilities with repayment or royalty mechanics. These tools and obligations do not mean a financing is imminent, but they belong in a complete runway analysis.
Primary sources: Q2 2026 earnings release and Q2 2026 Form 10-Q, both dated August 13, 2026.
The June 2026 annual meeting added another relevant governance item. Stockholders approved an amendment and restatement of the 2022 Stock Option and Incentive Plan that increased the share reserve by 7,000,000 shares. That amount equals roughly 6.0% of the common shares outstanding at March 31. It is not an immediate issuance of seven million shares, but it expands the pool available for future equity compensation and belongs in any dilution-aware analysis.
Fate’s leadership transition is part of the modern company story. Bob Valamehr, Ph.D., MBA, serves as President and Chief Executive Officer and is closely associated with Fate’s iPSC platform and scientific execution. His background is relevant because Fate is not a conventional single-asset biotech; it is a manufacturing-heavy, engineering-heavy platform company where scientific architecture and operational discipline are deeply linked.
The June 15, 2026 appointment of Laura Hamill to the Board of Directors adds a specific commercial-readiness angle to the governance story. Hamill is a biopharmaceutical commercial operations executive with more than three decades of industry experience. Fate highlighted her background in building commercial capabilities, launching therapies, market access, pricing, contracting and organizational design. She previously served as Executive Vice President, Worldwide Commercial Operations at Gilead Sciences, where Fate said she was responsible for approximately $22 billion in annual revenue and an organization of 2,500 employees. She also spent nearly two decades at Amgen and currently serves on the boards of BB Biotech AG and Jazz Pharmaceuticals.
| Holder disclosed in 2026 proxy | Shares / equivalents shown | Displayed ownership | Important qualification |
|---|---|---|---|
| Redmile-affiliated entities | 18.23M shown in the proxy total | 14.99% | Includes convertible-preferred equivalents subject to a 14.99% ownership blocker. Separate pre-funded warrants were not included in displayed beneficial ownership because of exercise limitations. |
| ARK Investment Management | 10.31M | 8.87% | Proxy figure was based on an older Schedule 13G/A and should not be treated as a real-time position. |
| Vanguard Group | 8.77M | 7.54% | The proxy noted a March 2026 internal realignment and possible future disaggregated filings by affiliated entities. |
| BlackRock | 7.85M | 6.75% | Beneficial ownership was attributed through multiple BlackRock subsidiaries and based on the cited Schedule 13G/A. |
A May 2026 Form 4 showed President and CEO Bahram Valamehr selling 28,946 common shares at a weighted-average price of $1.8822. Read in isolation, that can look like discretionary selling. The filing footnote states that the shares were automatically sold to cover tax withholding obligations connected with the vesting of 50,000 performance-based restricted stock units and that the transaction was not made at the executive’s discretion. A same-day transaction by Chief Legal and Compliance Officer Cindy Tahl carried the same sell-to-cover explanation.
One measurement, so that this is not only a description. On Stocktwits, read on September 30, 2026, the $FATE stream carried 6,543 watchers, message volume in the normal band at 54 out of 100, and a platform sentiment score of 54 out of 100, labelled neutral. Of the messages that carry a tag, 100% were bullish and none bearish, which on a thin sample says more about who bothers to tag than about conviction. The average of the twenty-two readings from August 31 is 49.5, in a range from 29 on August 31 to 79 on September 22: the second half of September was the strongest stretch of the month, and the score has come back to the midpoint since. Retail commentary on Reddit, Stocktwits and X/Twitter should be treated as non-professional trader sentiment, not factual confirmation. Bullish posts tend to emphasize autoimmune CAR-T enthusiasm, off-the-shelf manufacturing, the ISSCR and EULAR signals, RECLAIM-LN recruitment, FT839 IND clearance and runway into 2028. Bearish posts tend to emphasize dilution, past collaboration resets, small patient numbers, manufacturing complexity, trial-execution risk and the possibility that early data fail to scale. Both sides can illuminate crowd psychology; neither replaces primary filings and clinical data.
| Watchpoint | Dated evidence and remaining watchpoints | Window | What would de-risk the thesis |
|---|---|---|---|
| RECLAIM-LN enrollment | First patient dosed outpatient; NCT07570862 lists twelve U.S. sites, all recruiting, at the September 14, 2026 update; actual start July 27, 2026. | Enrollment target: completion in H1 2028 (company); registry primary completion July 2029 | Repeatable screen-to-dose conversion, broader site activation and no logistics bottleneck. |
| RECLAIM-LN efficacy | No Phase 2 efficacy data yet. | Primary endpoint at week 26 | Complete renal response with steroid reduction, preserved kidney function and durable safety. |
| FT839 COMPLETE | NCT07800871 posted September 2, 2026, Recruiting at one site (Fullerton, CA); 446 participants estimated, eight regimens with and without conditioning, five autoimmune diseases. | Registry start estimated October 2026; company enrollment update later in 2026 | First patient, acceptable safety, persistence and interpretable biological activity. |
| FT836 KRASwt CRC | Next cohort planned with multidose FT836 plus standard chemotherapy. | Clinical update H1 2027 | Replicated activity beyond two patients, durability and manageable combination safety. |
| Cash and financing | $153.8M at June 30; runway guidance into 2028; no ATM sales through quarter-end. | Each quarterly filing | Stable expense discipline and runway that remains ahead of key clinical readouts. |
The September conferences, Cantor on September 9, Wells Fargo on September 8–10 and H.C. Wainwright through September 16, and the CCR West presentation of September 18 have passed. The next confirmed presentations are the ACR posters on November 8–9 at 10:30 a.m.–12:30 p.m. ET. These appearances must be distinguished from trial enrollment and regulatory milestones.
Earlier announcement — September 16: four ACR presentations on November 8–9.
Fate announced September 16 that four abstracts were selected for ACR Convergence 2026, held November 6–11 in Orlando. FT839’s preclinical work and COMPLETE trial are scheduled for November 8; FT819 outpatient administration, biomarker/quality-of-life research and a patient-perspective study are scheduled for November 9. Poster sessions run 10:30 a.m.–12:30 p.m. ET on both dates.
The announcement previews clinical, translational and patient-preference material, including FT819 without conditioning chemotherapy. It does not provide a new numerical efficacy dataset or establish approval. The CCR West presentation of September 18, covering previously disclosed FT819 data and FT839 preclinical work, has taken place; it is distinct from the November ACR program.
Read the FATE Deep Dive Open Biotech Catalyst CalendarEditorial review: October 4, 2026. Each primary disclosure, financial period, registry observation and market snapshot retains its own reference date.
Market cards and ownership fields retain their stated provider observation dates. The older September 4 valuation example is historical. Financial figures are from dated SEC filings and company releases; derived quarterly figures are residuals of cumulative reports. The retail-sentiment paragraph is the September 30 Stocktwits snapshot.
The trial of FT819, Fate’s off-the-shelf iPSC-derived CD19 CAR T-cell product, in lupus nephritis. The first patient was dosed as announced on August 13, 2026, as an outpatient with same-day discharge. The study targets about 53 patients, with enrolment completion targeted in the first half of 2028.
It supports the RECLAIM-LN programme. A grant from the California Institute for Regenerative Medicine is non-dilutive money, which is the part that matters for a company of this size: it funds work without enlarging the share count.
$153.8 million of cash and investments at June 30, 2026, with company guidance that operations are funded into 2028, against a second-quarter 2026 net loss of $30.2 million, or $0.25 per share.
119,820,514 common shares on the Form 10-Q cover at August 6, 2026. On top of that the second-quarter filing reports 3.894 million pre-funded warrants and 13.775 million common-share equivalents from convertible preferred stock, with options and restricted stock units adding further potential dilution. Market-data providers may carry a smaller share count than the filed one.
Programs share platform features, so evidence may affect expectations across assets; this does not prove higher volatility than every single-asset biotech. A good update can raise the probability assigned to FT819 and the perceived option value of FT839, FT522 and the wider iPSC engine at the same time; a poor one can compress all of them together, even where individual programmes remain scientifically alive.
Every Merlintrader stock hub, catalyst update and market brief is published to Telegram the moment it goes live. No paywall, no spam, just the research.
Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $FATE or any other security.
Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases and market-data providers, and are stated with their reference dates. Data can change without notice, and figures published before a results release become outdated the moment that release is issued. Merlintrader makes no representation that the information is complete or current at the time of reading. Readers should verify every figure against the primary source before acting on it.
Biotechnology and healthcare companies carry binary risk. Clinical trials fail, regulatory decisions go against the applicant, approval does not guarantee commercial uptake, and development-stage companies frequently raise equity at whatever price the market will bear. A single readout can change the value of the business overnight in either direction, and companies at this stage can lose all of their value. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate.
Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz and Stocktwits, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.
This content is for informational and educational purposes only and does not constitute financial advice, investment advice, an offer, solicitation, or recommendation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile. Clinical-stage companies can experience sharp price moves around data, regulatory updates, financings, trial delays and market sentiment. Readers should conduct independent research and consult a licensed financial adviser where appropriate. Merlintrader may discuss securities that are volatile, illiquid or subject to significant event risk. Facts, figures and links should be checked against primary sources at the time of reading, as company data, regulatory timelines and clinical-trial status can change.
